JAMP Pharma Group is active in all sectors of the pharmaceutical industry with our JAMP Pharma generic products, our Orimed Pharma branded products, our Wampole and Laboratoire Suisse natural health products, and our Cosmetic Import beauty and personal care products.
JAMP Pharma Group has also made a recent major investment in biosimilars—one of the fastest growing markets in the industry—with the launch of its BIOJAMP division.
For nearly 35 years, we have been committed to supporting healthcare professionals so that they may focus on what matters most: the well-being of Canadians. We have made healthcare solutions more accessible and affordable for both patients and consumers.
As we look to the future, we are committed to ensuring that our diversified product portfolio remains accessible to all, while guaranteeing the most reliable supply in Canada.
The JAMP Pharma Group launches Pr JAMP Apremilast, a new generic alternative for the treatment of plaque psoriasis and psoriatic arthritis
The JAMP Pharma Group launches Apremilast, a specialty generic, offering a more affordable alternative to the reference product Otezla® (marketed by Amgen Canada Inc.). The JAMP Pharma Group, a leader in product launches1, expands its line of specialty products, contributing to its ambition to offer healthcare professionals and patients services…
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
Expanded partnership covers biosimilar candidates in immunology and oncology REYKJAVIK, ICELAND & BOUCHERVILLE, QC (October 17, 2022) – Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and the JAMP Pharma Group (JAMP Pharma), a Canadian owned pharmaceutical company headquartered in…
BIOJAMP, News and events, Press release
JAMP Pharma Launches SIMLANDI™, a NEW High-Concentration, Low Volume, Citrate-Free formulation, Biosimilar to Humira®, in Canada
SIMLANDI™ provides patients access to high-concentration, low volume, citrate-free formulations of adalimumab, in 40 mg/0.4 mL and 80 mg/0.8 mL presentations, not available in Canada before this week SIMLANDI™ is the first adalimumab biosimilar product launched by a Canadian-based company, JAMP Pharma Group The creation of BIOJAMP™ Pharma…
New launches, Press release